Osteocalcin and Metabolic Syndrome

Area of Science:

• Endocrinology
• Metabolic Disorders
• Bone Metabolism

Background:

• Metabolic syndrome is a cluster of conditions increasing the risk of heart disease, stroke, and diabetes.
• Insulin resistance is a key feature of metabolic syndrome.
• Osteocalcin (OC), a bone-derived hormone, has shown potential in improving insulin sensitivity and stimulating insulin production.

Purpose of the Study:

• To investigate the relationship between serum osteocalcin levels and the components of metabolic syndrome.
• To explore the potential therapeutic role of osteocalcin in managing metabolic syndrome.

Main Methods:

• A cross-sectional study was conducted on 115 adult patients meeting NCEP-ATP III guidelines for metabolic syndrome.
• Patients with specific endocrine, bone, liver, or kidney disorders were excluded.
• Serum osteocalcin levels were measured and correlated with metabolic syndrome parameters.

Main Results:

• Increased serum osteocalcin showed a significant inverse correlation with fasting blood glucose (r = -0.748, P < 0.05).
• Serum osteocalcin demonstrated a significant positive correlation with serum HDL levels (r = 0.617, P < 0.01).
• Individuals with fewer metabolic syndrome components had significantly higher serum osteocalcin levels (P < 0.01).

Conclusions:

• Serum osteocalcin levels are significantly associated with improved glucose metabolism and lipid profiles in patients with metabolic syndrome.
• Higher osteocalcin levels correlate with fewer metabolic syndrome components, suggesting a potential protective metabolic impact.
• Osteocalcin may represent a novel therapeutic target for mitigating atherosclerotic risk in metabolic syndrome.